First Reconstructive Surgery under Compassionate Use and First U.S. Patient Treated
Boston, MA and Switzerland, 10 October 2024 – CUTISS AG, a life sciences company at the forefront of tissue engineering therapy and regenerative medicine, announced the first ever grafting of denovoSkin™, its autologous, bio-engineered dermo-epidermal skin graft, in a compassionate reconstructive procedure, with the patient also being the first ever U.S. case for the company. The procedure was authorized by the U.S. Food & Drug Administration (FDA) under single patient Investigational New...| CUTISS
